Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Utah Medical strikes back

This article was originally published in The Gray Sheet

Executive Summary

HHS has six months from Utah Medical's July 12 bid for reconsideration to honor or deny the firm's request for remedies - including over $7 mil. in damages - at which point the company may pursue legal action, according to CEO Kevin Cornwell. Utah Medical has alleged misconduct on the part of FDA employees during the inspections, review and subsequent enforcement actions that culminated in FDA seeking a permanent sales injunction against the company in Utah federal court. Though Utah Medical emerged victorious in October 2005, it claims the ordeal has done "irreparable harm" to the company's reputation (1"The Gray Sheet" Feb. 20, 2006, p. 13)...

You may also be interested in...

Utah Medical Seeks Reparations From FDA For Alleged FDA Misconduct

Utah Medical is considering whether to file a lawsuit against FDA after the Department of Health & Human Services denied its "administrative claim" seeking payments and other settlement actions based on alleged misconduct by FDA employees

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding

GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts